亚洲精品成人免费_91女神娇喘疯狂3p之夜_精品韩国一级久久_av毛片网_www超碰com_午夜视频体内射.COM.COM

美國Nuron Biotech 
nuron目前正在對產品在兩個方面的疾病：中樞神經系統（CNS）和疫苗

Nuron Biotech is focused on innovative and improved specialty biologics and vaccines. Nuron’s vision is to bring better biologics with innovative and enhanced product profiles to market for the better health of patients. Nuron’s management team consists of proven veteran industry executives who have made significant contributions in developing, launching and managing the life cycle of various biologics while at Pfizer and other biotechnology companies.

Nuron is currently working on products in two disease areas: Central Nervous System (CNS) and Vaccines. The first product, NU100, is a proprietary recombinant human interferon beta-1b for the treatment of Multiple Sclerosis (MS) and developed as New Molecular Entity (NME). It’s an improved interferon beta product manufactured using proprietary process technology. It is a liquid product with an autoinjector and essentially aggregate-free compared to other marketed interferon beta products. Absence of aggregates in NU100 should reauslt in lower immune response in patients which should lead to improved tolerability, safety and efficacy in the long term. Nuron Initiated Phase 3 clinical studies in Oct. 2011.

Nuron has acquired assets relating to the vaccine HibTITER? (Haemophilus b Conjugate Vaccine (Diphtheria CRM197 Protein Conjugate)) from Wyeth, a wholly owned subsidiary of Pfizer, for the U.S. and many other markets, including Japan and Korea. Nuron’s strategy to relaunch HibTITER? in the US market has received positive opinion from the FDA.

NU400 is a long-acting version of Nuron’s proprietary recombinant human interferon beta-1b (NU100) produced using a combination of NU100 and proprietary pegylation technology. NU400 should carry the benefit of NU100 with reduced injection frequency, potentially semi-monthly or monthly injection for better patient compliance. This product supports Nuron’s long-term life cycle strategy for MS.

Nuron is currently in discussions with other biotechnology companies to expand the company’s portfolio in the areas of vaccines.